JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

Novartis AG

Slēgts

116.79 0.8

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

116.52

Max

116.9

Galvenie mērījumi

By Trading Economics

Ienākumi

418M

4B

Pārdošana

660M

14B

P/E

Sektora vidējais

16.809

34.393

EPS

2.42

Dividenžu ienesīgums

3.46

Peļņas marža

28.18

Darbinieki

75,883

EBITDA

-5.8B

4.9M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+5.92% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.46%

2.54%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-11B

228B

Iepriekšējā atvēršanas cena

115.99

Iepriekšējā slēgšanas cena

116.79

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Novartis AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. aug. 05:47 UTC

Iegādes, apvienošanās, pārņemšana

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

2025. g. 17. jūl. 14:26 UTC

Peļņas

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

2025. g. 17. jūl. 06:49 UTC

Peļņas

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

2025. g. 17. jūl. 05:41 UTC

Peļņas

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

2025. g. 8. aug. 11:26 UTC

Tirgus saruna

Novartis Is Getting Closer to Midterm Targets -- Market Talk

2025. g. 8. aug. 11:07 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Novartis Has Room to Accelerate Dealmaking -- Market Talk

2025. g. 8. aug. 10:51 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

2025. g. 5. aug. 10:40 UTC

Tirgus saruna

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

2025. g. 17. jūl. 11:36 UTC

Tirgus saruna

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

2025. g. 17. jūl. 11:26 UTC

Tirgus saruna

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

2025. g. 17. jūl. 07:14 UTC

Tirgus saruna

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

2025. g. 17. jūl. 07:02 UTC

Tirgus saruna
Peļņas

Novartis's Results Look Impressive -- Market Talk

2025. g. 17. jūl. 05:09 UTC

Peļņas

Novartis 2Q Sales Grew 11% at Constant Currency

2025. g. 17. jūl. 05:08 UTC

Peļņas

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

2025. g. 17. jūl. 05:06 UTC

Peļņas

Novartis: Mehta's Appointment Is Effective March 2026

2025. g. 17. jūl. 05:05 UTC

Peļņas

Novartis: Harry Kirsch Retires After 22 Years With Company

2025. g. 17. jūl. 05:05 UTC

Peļņas

Novartis Names Mukul Mehta as CFO

2025. g. 17. jūl. 05:04 UTC

Peļņas

Analysts Saw Novartis 2Q Net Profit at $3.815B

2025. g. 17. jūl. 05:04 UTC

Peļņas

Analysts Saw Novartis 2Q Core Operating Profit at $5.75B

2025. g. 17. jūl. 05:04 UTC

Peļņas

Analysts Saw Novartis 2Q Sales at $14.17B

2025. g. 17. jūl. 05:04 UTC

Peļņas

Novartis 2Q Core Operating Profit $5.925B

2025. g. 17. jūl. 05:04 UTC

Peļņas

Novartis 2Q Oper Pft $4.86B

2025. g. 17. jūl. 05:03 UTC

Peļņas

Novartis 2Q Sales $14.05B

2025. g. 17. jūl. 05:01 UTC

Peļņas

Novartis: Buyback to Be Completed by End of 2027

2025. g. 17. jūl. 05:01 UTC

Peļņas

Novartis Starting Buyback of Up to $10B

2025. g. 17. jūl. 05:01 UTC

Peļņas

Novartis Backs 2025 Sales View

2025. g. 17. jūl. 05:01 UTC

Peļņas

Novartis Had Guided for Low Double-Digit Growth in Core Operating Profit at Constant Currency

2025. g. 17. jūl. 05:01 UTC

Peļņas

Novartis Expects 2025 Core Operating Profit to Grow by Low Teens at Constant Currency

2025. g. 17. jūl. 05:00 UTC

Peļņas

Novartis Raises 2025 Earnings View

2025. g. 17. jūl. 05:00 UTC

Peļņas

Novartis AG 2Q Adj EPS $2.42

Salīdzinājums

Cenas izmaiņa

Novartis AG Prognoze

Cenas mērķis

By TipRanks

5.92% augšup

Prognoze 12 mēnešiem

Vidējais 122.78 USD  5.92%

Augstākais 137.561 USD

Zemākais 108 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Novartis AG — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

3 ratings

0

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 112.63Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.